Advaxis (ADXS) was Reiterated by Barclays to “Overweight” according to the research note released today. The brokerage firm has raised the Price Target to $ 20 from a previous price target of $15 . Barclays advised their investors in a research report released on Aug 3, 2016.
Advaxis opened for trading at $10.34 and hit $11.3499 on the upside on Tusday, eventually ending the session at $11.08, with a gain of 30.81% or 2.61 points. The heightened volatility saw the trading volume jump to 64,18,753 shares. Company has a market cap of $381 M.
In a different news, on May 13, 2016, Thomas J Mckearn (director) sold 4,100 shares at $7.45 per share price. According to the SEC, on May 2, 2016, Robert Petit (Chief Scientific Officer) sold 2,785 shares at $7.51 per share price. On May 2, 2016, Daniel O’connor (Chief Executive Officer) sold 8,237 shares at $7.51 per share price, according to the Form-4 filing with the securities and exchange commission.
Advaxis Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy axalimogene filolisbac (ADXS-HPV) targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer Phase I/II in head and neck cancer and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.